Tumor necrosis factor-related apoptosis-inducing ligand and cardiovascular disease

Atherosclerosis

Volumn 215, Issue 2, 2011, Pages 279-280

  Ebert, Thomas ^a   Fasshauer, Mathias ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; ECG ABNORMALITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEART DEATH; HEART FAILURE; HUMAN; INFLAMMATION; INTERNATIONAL CLASSIFICATION OF DISEASES; MORBIDITY; MORTALITY; NONHUMAN; NOTE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

CARDIOVASCULAR DISEASES; COHORT STUDIES; HUMANS; ITALY; PROGNOSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79953063304     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.12.042     Document Type: Note

References (10)

1. Pascual-Figal D.A., Domingo M., Casas T., et al. Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. Eur Heart J 2008, 29:1011-1018.
2. Bots M.L., Hoes A.W., Koudstaal P.J., Hofman A., Grobbee D.E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997, 96:1432-1437.
3. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
4. Pitti R.M., Marsters S.A., Ruppert S., et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271:12687-12690.
5. Secchiero P., Corallini F., Ceconi C., et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS ONE 2009, 4:e4442.
6. Michowitz Y., Goldstein E., Roth A., et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005, 45:1018-1024.
7. Niessner A., Hohensinner P.J., Rychli K., et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009, 30:789-796.
8. Secchiero P., Candido R., Corallini F., et al. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation 2006, 114:1522-1530.
9. Sato K., Niessner A., Kopecky S.L., et al. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 2006, 203:239-250.
10. Soria J.C., Smit E., Khayat D., et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010, 28:1527-1533.